256 related articles for article (PubMed ID: 34384540)
1. Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial.
Qadri F; Khanam F; Liu X; Theiss-Nyland K; Biswas PK; Bhuiyan AI; Ahmmed F; Colin-Jones R; Smith N; Tonks S; Voysey M; Mujadidi YF; Mazur O; Rajib NH; Hossen MI; Ahmed SU; Khan A; Rahman N; Babu G; Greenland M; Kelly S; Ireen M; Islam K; O'Reilly P; Scherrer KS; Pitzer VE; Neuzil KM; Zaman K; Pollard AJ; Clemens JD
Lancet; 2021 Aug; 398(10301):675-684. PubMed ID: 34384540
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial.
Jin C; Gibani MM; Moore M; Juel HB; Jones E; Meiring J; Harris V; Gardner J; Nebykova A; Kerridge SA; Hill J; Thomaides-Brears H; Blohmke CJ; Yu LM; Angus B; Pollard AJ
Lancet; 2017 Dec; 390(10111):2472-2480. PubMed ID: 28965718
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study.
Mitra M; Shah N; Ghosh A; Chatterjee S; Kaur I; Bhattacharya N; Basu S
Hum Vaccin Immunother; 2016 Apr; 12(4):939-45. PubMed ID: 26901576
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial.
Kumar Rai G; Saluja T; Chaudhary S; Tamrakar D; Kanodia P; Giri BR; Shrestha R; Uranw S; Kim DR; Yang JS; Park IY; Kyung SE; Vemula S; Reddy E J; Kim B; Gupta BP; Jo SK; Ryu JH; Park HK; Shin JH; Lee Y; Kim H; Kim JH; Mojares ZR; Wartel TA; Sahastrabuddhe S
Lancet Infect Dis; 2022 Apr; 22(4):529-540. PubMed ID: 34942090
[TBL] [Abstract][Full Text] [Related]
5. Vaccines for preventing typhoid fever.
Milligan R; Paul M; Richardson M; Neuberger A
Cochrane Database Syst Rev; 2018 May; 5(5):CD001261. PubMed ID: 29851031
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of typhoid conjugate vaccine: final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children.
Patel PD; Liang Y; Meiring JE; Chasweka N; Patel P; Misiri T; Mwakiseghile F; Wachepa R; Banda HC; Shumba F; Kawalazira G; Dube Q; Nampota-Nkomba N; Nyirenda OM; Girmay T; Datta S; Jamka LP; Tracy JK; Laurens MB; Heyderman RS; Neuzil KM; Gordon MA;
Lancet; 2024 Feb; 403(10425):459-468. PubMed ID: 38281499
[TBL] [Abstract][Full Text] [Related]
7. Assessment of vaccine herd protection in a cluster-randomised trial of Vi conjugate vaccine against typhoid fever: results of further analysis.
Khanam F; Kim DR; Liu X; Voysey M; Pitzer VE; Zaman K; Pollard AJ; Qadri F; Clemens JD
EClinicalMedicine; 2023 Apr; 58():101925. PubMed ID: 37090439
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials.
Bhutta ZA; Capeding MR; Bavdekar A; Marchetti E; Ariff S; Soofi SB; Anemona A; Habib MA; Alberto E; Juvekar S; Khan RM; Marhaba R; Ali N; Malubay N; Kawade A; Saul A; Martin LB; Podda A
Lancet Infect Dis; 2014 Feb; 14(2):119-29. PubMed ID: 24290843
[TBL] [Abstract][Full Text] [Related]
9. Seroefficacy of Vi Polysaccharide-Tetanus Toxoid Typhoid Conjugate Vaccine (Typbar TCV).
Voysey M; Pollard AJ
Clin Infect Dis; 2018 Jun; 67(1):18-24. PubMed ID: 29351594
[TBL] [Abstract][Full Text] [Related]
10. Immune responses in children after vaccination with a typhoid Vi-tetanus toxoid conjugate vaccine in Bangladesh.
Khanam F; Babu G; Rahman N; Liu X; Rajib NH; Ahmed SU; Hossen MI; Biswas PK; Kelly S; Thesis-Nyland K; Mujadidi Y; McMillan NAJ; Pollard AJ; Clemens JD; Qadri F
Vaccine; 2023 May; 41(19):3137-3140. PubMed ID: 37061369
[TBL] [Abstract][Full Text] [Related]
11. Vi-Vaccinations Induce Heterogeneous Plasma Cell Responses That Associate With Protection From Typhoid Fever.
Cross DL; Verheul MK; Leipold MD; Obermoser G; Jin C; Jones E; Starr JS; Mohorianu I; Blohmke CJ; Maecker HT; Napolitani G; Hill J; Pollard AJ
Front Immunol; 2020; 11():574057. PubMed ID: 33424833
[TBL] [Abstract][Full Text] [Related]
12. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India.
Sur D; Ochiai RL; Bhattacharya SK; Ganguly NK; Ali M; Manna B; Dutta S; Donner A; Kanungo S; Park JK; Puri MK; Kim DR; Dutta D; Bhaduri B; Acosta CJ; Clemens JD
N Engl J Med; 2009 Jul; 361(4):335-44. PubMed ID: 19625715
[TBL] [Abstract][Full Text] [Related]
13. IgA and IgG1 Specific to Vi Polysaccharide of
Dahora LC; Jin C; Spreng RL; Feely F; Mathura R; Seaton KE; Zhang L; Hill J; Jones E; Alam SM; Dennison SM; Pollard AJ; Tomaras GD
Front Immunol; 2019; 10():2582. PubMed ID: 31781100
[TBL] [Abstract][Full Text] [Related]
14. Assessing the Impact of a Vi-polysaccharide Conjugate Vaccine in Preventing Typhoid Infection Among Bangladeshi Children: A Protocol for a Phase IIIb Trial.
Theiss-Nyland K; Qadri F; Colin-Jones R; Zaman K; Khanam F; Liu X; Voysey M; Khan A; Hasan N; Ashher F; Farooq YG; Pollard AJ; Clemens JD
Clin Infect Dis; 2019 Mar; 68(Suppl 2):S74-S82. PubMed ID: 30845333
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial.
Shakya M; Voysey M; Theiss-Nyland K; Colin-Jones R; Pant D; Adhikari A; Tonks S; Mujadidi YF; O'Reilly P; Mazur O; Kelly S; Liu X; Maharjan A; Dahal A; Haque N; Pradhan A; Shrestha S; Joshi M; Smith N; Hill J; Clarke J; Stockdale L; Jones E; Lubinda T; Bajracharya B; Dongol S; Karkey A; Baker S; Dougan G; Pitzer VE; Neuzil KM; Shrestha S; Basnyat B; Pollard AJ;
Lancet Glob Health; 2021 Nov; 9(11):e1561-e1568. PubMed ID: 34678198
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian Children.
Patel PD; Patel P; Liang Y; Meiring JE; Misiri T; Mwakiseghile F; Tracy JK; Masesa C; Msuku H; Banda D; Mbewe M; Henrion M; Adetunji F; Simiyu K; Rotrosen E; Birkhold M; Nampota N; Nyirenda OM; Kotloff K; Gmeiner M; Dube Q; Kawalazira G; Laurens MB; Heyderman RS; Gordon MA; Neuzil KM;
N Engl J Med; 2021 Sep; 385(12):1104-1115. PubMed ID: 34525285
[TBL] [Abstract][Full Text] [Related]
17. Typhoid conjugate vaccine effectiveness in Malawi: evaluation of a test-negative design using randomised, controlled clinical trial data.
Liang Y; Driscoll AJ; Patel PD; Datta S; Voysey M; French N; Jamka LP; Henrion MYR; Ndeketa L; Laurens MB; Heyderman RS; Gordon MA; Neuzil KM
Lancet Glob Health; 2023 Jan; 11(1):e136-e144. PubMed ID: 36442498
[TBL] [Abstract][Full Text] [Related]
18. Prevention of Typhoid by Vi Conjugate Vaccine and Achievable Improvements in Household Water, Sanitation, and Hygiene: Evidence From a Cluster-Randomized Trial in Dhaka, Bangladesh.
Tadesse BT; Khanam F; Ahmmed F; Im J; Islam MT; Kim DR; Kang SSY; Liu X; Chowdhury F; Ahmed T; Binte Aziz A; Hoque M; Park J; Pak G; Zaman K; Khan AI; Pollard AJ; Kim JH; Marks F; Qadri F; Clemens JD
Clin Infect Dis; 2022 Nov; 75(10):1681-1687. PubMed ID: 35412603
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of typhoid vaccines against culture-confirmed Salmonella Typhi in typhoid endemic countries: a systematic review and meta-analysis.
Batool R; Qamar ZH; Salam RA; Yousafzai MT; Ashorn P; Qamar FN
Lancet Glob Health; 2024 Apr; 12(4):e589-e598. PubMed ID: 38485426
[TBL] [Abstract][Full Text] [Related]
20. Six-month follow up of a randomized clinical trial-phase I study in Indonesian adults and children: Safety and immunogenicity of Salmonella typhi polysaccharide-diphtheria toxoid (Vi-DT) conjugate vaccine.
Medise BE; Soedjatmiko S; Rengganis I; Gunardi H; Sekartini R; Koesno S; Satari HI; Hadinegoro SR; Yang JS; Excler JL; Sahastrabuddhe S; Puspita M; Sari RM; Bachtiar NS
PLoS One; 2019; 14(2):e0211784. PubMed ID: 30759132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
